|
|
Article: Ramelteon: A novel melatonin receptor agonist for the treatment of insomnia
- Article from:
- Formulary
- Article date:
- May 1, 2005
- Author:
-
;
;
|
Copyright informationCopyright Advanstar Communications, Inc. May 2005. Provided by ProQuest LLC. (Hide copyright information)
|
Abstract
Ramelteon (Takeda Pharmaceuticals) is a selective melatonin receptor agonist awaiting FDA approval for the treatment of insomnia. Unlike the currently prescribed hypnotic agents that work by targeting gamma-aminobutyric acid (GABA) receptors, ramelteon offers a novel mechanism of action, specifically targeting the MT^sub 1^ and MT^sub 2^ receptors in the brain, which are thought to play a role in regulating sedation and circadian rhythms. Ramelteon is characterized by undergoing extensive first-pass metabolism along with having high oral bioavailability. Results of phase 2 clinical trials have demonstrated that ramelteon-treated patients had significantly shorter sleep onset ...
Related newspaper, magazine, and journal articles:
|
|
Article: Abundance of insomnia therapies in the pipeline.(Neuropsychiatric Medicine)
Clinical Psychiatry News;
December 1, 2005 ;
700+ words
......industry envisions the insomnia market as a field of...an exciting time in insomnia. There's a lot of movement...stems from the fact that insomnia is extremely common...prescribed off-label for insomnia, the benzodiazepine...off-label use of agents for insomnia. Moreover, surveys ...
|
|